ATE480237T1 - Tumorhemmende nitroacridin-zusammensetzungen - Google Patents

Tumorhemmende nitroacridin-zusammensetzungen

Info

Publication number
ATE480237T1
ATE480237T1 AT01910944T AT01910944T ATE480237T1 AT E480237 T1 ATE480237 T1 AT E480237T1 AT 01910944 T AT01910944 T AT 01910944T AT 01910944 T AT01910944 T AT 01910944T AT E480237 T1 ATE480237 T1 AT E480237T1
Authority
AT
Austria
Prior art keywords
compositions
inhibiting
tumor
nitroacridine
metastases
Prior art date
Application number
AT01910944T
Other languages
English (en)
Inventor
Tiwari Raj
Daniel Miller
Jerzy Konopa
Barbara Wysocka-Skrzela
Original Assignee
New York Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College filed Critical New York Medical College
Application granted granted Critical
Publication of ATE480237T1 publication Critical patent/ATE480237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01910944T 2000-02-18 2001-02-16 Tumorhemmende nitroacridin-zusammensetzungen ATE480237T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18352900P 2000-02-18 2000-02-18
PCT/US2001/005276 WO2001060351A2 (en) 2000-02-18 2001-02-16 Nitroacridine/tumor inhibitor compositions

Publications (1)

Publication Number Publication Date
ATE480237T1 true ATE480237T1 (de) 2010-09-15

Family

ID=22673188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910944T ATE480237T1 (de) 2000-02-18 2001-02-16 Tumorhemmende nitroacridin-zusammensetzungen

Country Status (13)

Country Link
US (1) US7622478B2 (de)
EP (1) EP1261325B1 (de)
AT (1) ATE480237T1 (de)
AU (1) AU2001238499A1 (de)
CA (1) CA2400403C (de)
CY (1) CY1111289T1 (de)
DE (1) DE60143023D1 (de)
DK (1) DK1261325T3 (de)
ES (1) ES2352175T3 (de)
IL (2) IL150978A0 (de)
MX (1) MXPA02008014A (de)
PT (1) PT1261325E (de)
WO (1) WO2001060351A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US8647627B2 (en) * 2011-01-13 2014-02-11 Oncbiomune, L.L.C. Composition for a cancer vaccine
WO2021198442A1 (en) * 2020-04-01 2021-10-07 Vestlandets Innovasjonsselskap As Isoquinoline derivatives for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694447A (en) 1970-03-10 1972-09-26 Smith Kline French Lab Complexes of phosphanilic acid and 9-amino-3-nitroacridine
PL106752B1 (pl) 1976-02-25 1980-01-31 Politechnika Gdanska Sposob otrzymywania nowych 1-nitro-9-alkiloaminoalkiloaminoakrydyn lub ich soli
PL126407B1 (en) 1980-04-23 1983-07-30 Politechnika Gdanska Process for preparing 1-nitro-9-hydroxyalkylaminoacridines or their salts
NZ200715A (en) 1982-05-24 1986-06-11 New Zealand Dev Finance Acridine derivatives and pharmaceutical compositions containing such
US4985436A (en) 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
JP2783680B2 (ja) 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体
JPH05331070A (ja) 1992-02-07 1993-12-14 Takeda Chem Ind Ltd Ｔｎｐとインターロイキンとを含有してなる抗腫瘍剤
US5696131A (en) 1993-01-22 1997-12-09 Xenova Limited Treatment of cancers
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
AU2284595A (en) 1994-04-29 1995-11-29 Center For Molecular Medicine And Immunology Composition for delivery of toxic radioisotopes to the cell nucleus and use
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
US5529989A (en) 1995-01-09 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Pancratistatin prodrug
KR0160110B1 (ko) 1995-05-24 1998-12-01 한영복 항암제 조성물
WO1999016889A1 (en) * 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999034788A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of phenstatin and prodrugs thereof
WO1999058126A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
JP2002537262A (ja) * 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法

Also Published As

Publication number Publication date
MXPA02008014A (es) 2004-04-05
US7622478B2 (en) 2009-11-24
CA2400403A1 (en) 2001-08-23
US20020037831A1 (en) 2002-03-28
AU2001238499A1 (en) 2001-08-27
CA2400403C (en) 2011-07-19
EP1261325B1 (de) 2010-09-08
ES2352175T3 (es) 2011-02-16
DE60143023D1 (de) 2010-10-21
WO2001060351A3 (en) 2002-01-24
WO2001060351A2 (en) 2001-08-23
IL150978A0 (en) 2003-02-12
PT1261325E (pt) 2010-12-10
EP1261325A2 (de) 2002-12-04
CY1111289T1 (el) 2015-08-05
IL150978A (en) 2010-06-30
DK1261325T3 (da) 2010-12-20

Similar Documents

Publication Publication Date Title
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
ATE541571T1 (de) Diarylhydantoin-verbindung
CY1107637T1 (el) Θεραπευτικη αγωγη καρκινου προστατη με αντισωματα αντι - erbb2
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
HRP20050228A2 (en) Novel phenanthridines
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
ATE368466T1 (de) Androgensyntheseinhibitoren
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
DE60329326D1 (de) Tace inhibitoren
NO20015892D0 (no) Inhibitorer av metallproteinaser
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE287403T1 (de) 6-phenylbenzonaphthyidine
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
NO20031745L (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
WO2001028593A3 (en) Conjugates useful in the treatment of prostate cancer
PT1276722E (pt) Inibidores de naftamidina-uroquinase
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
ATE364037T1 (de) Tryptasehemmer
MXPA03001440A (es) Compuestos de trioxepano novedosos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1261325

Country of ref document: EP